Sign Up to like & get
recommendations!
2
Published in 2022 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03893-z
Abstract: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. The clinical value of repeat rebiopsy in…
read more here.
Keywords:
rebiopsy;
lung;
first rebiopsy;
repeat rebiopsy ... See more keywords